Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

Xywav is the first FDA approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years Xywav contains 92 percent less sodium per nightly dose than sodium oxybate, a curre... Biopharmaceuticals, Neurology, FDA Jazz Pharmaceuticals, Xywav, Cataplexy, Narcolepsy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news